June 22, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NovoCure Limited (“Novocure” or “the Company”) (NASDAQ: NVCR). Investors who purchased Novocure securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Novocure has violated federal… read more
June 22, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accenture plc (“Accenture” or “the Company”) (NYSE: ACN). Investors who purchased Accenture securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Accenture has violated federal… read more
June 17, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gildan Activewear Inc. (“Gildan” or “the Company”) (NYSE: GIL). Investors who purchased Gildan securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Gildan has violated… read more
June 16, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Oxford Industries, Inc. (“Oxford” or “the Company”) (NYSE: OXM). Investors who purchased Oxford securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Oxford has violated… read more
June 15, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Borr Drilling Limited (“Borr” or “the Company”) (NYSE: BORR). Investors who purchased Borr securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Borr has violated… read more
June 12, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of United Homes Group, Inc. (“United Homes” or “the Company”) (NASDAQ: UHG). Investors who purchased United Homes securities prior to May 19, 2025, and continue to hold to the present, are encouraged… read more
June 12, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Kemper Corporation (“Kemper” or “the Company”) (NYSE: KMPR). Investors who purchased Kemper securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Kemper has violated federal… read more
June 11, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AECOM (“AECOM” or “the Company”) (NYSE: ACM). Investors who purchased AECOM securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether AECOM has violated federal securities… read more
June 10, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Wealthfront Corporation (“Wealthfront” or “the Company”) (NASDAQ: WLTH). Investors who purchased Wealthfront securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Wealthfront has violated federal… read more
June 10, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PVH Corp. (“PVH” or “the Company”) (NYSE: PVH). Investors who purchased PVH securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether PVH has violated federal… read more
June 10, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of B&G Foods, Inc. (“B&G” or “the Company”) (NYSE: BGS). Investors who purchased B&G securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether B&G has violated… read more
June 9, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Compass, Inc. (“Compass” or “the Company”) (NYSE: COMP). Investors who purchased Compass securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Compass has violated federal… read more
June 9, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of The Gap Inc. (“Gap” or “the Company”) (NYSE: GAP). Investors who purchased Gap securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Gap has violated… read more
June 8, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medpace Holdings, Inc. (“Medpace” or “the Company”) (NASDAQ: MEDP). Investors who purchased Medpace securities prior to April 22, 2025, and continue to hold to the present, are encouraged to obtain additional… read more
June 8, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of New Era Energy & Digital, Inc. (f/k/a New Era Helium Inc.) (“New Era” or “the Company”) (NASDAQ: NUAI). Investors who purchased New Era securities prior to November 6, 2024, and continue… read more
June 8, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gossamer Bio, Inc. (“Gossamer” or “the Company”) (NASDAQ: GOSS). Investors who purchased Gossamer securities prior to June 16, 2025, and continue to hold to the present, are encouraged to obtain additional… read more
June 8, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. (“Aldeyra” or “the Company”) (NASDAQ: ALDX). Investors who purchased Aldeyra securities prior to November 3, 2023, and continue to hold to the present, are encouraged to obtain additional… read more
June 8, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADC Therapeutics SA (“ADC” or “the Company”) (NYSE: ADCT). Investors who purchased ADC securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether ADC has violated… read more
June 5, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biogen Inc. (“Biogen” or “the Company”) (NASDAQ: BIIB). Investors who purchased Biogen securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Biogen has violated federal… read more
June 4, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (“Fulcrum” or “the Company”) (NASDAQ: FULC). Investors who purchased Fulcrum securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Fulcrum has violated… read more
June 4, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Abivax S.A. (“Abivax” or “the Company”) (NASDAQ: ABVX). Investors who purchased Abivax securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Abivax has violated federal… read more
June 4, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medline Inc. (“Medline” or “the Company”) (NASDAQ: MDLN). Investors who purchased Medline securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Medline has violated federal… read more
June 3, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PrimeEnergy Resources Corporation (“PrimeEnergy” or “the Company”) (NASDAQ: PNRG). Investors who purchased PrimeEnergy securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether PrimeEnergy has violated… read more
June 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sivers Semiconductors AB (“Sivers” or “the Company”) (OTCMKTS: SIVEF). Investors who purchased Sivers securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Sivers has violated… read more
June 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Oculis Holding AG (“Oculis” or “the Company”) (NASDAQ: OCS). Investors who purchased Oculis securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Oculis has violated… read more
June 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Angi Inc. (“Angi” or “the Company”) (NASDAQ: ANGI). Investors who purchased Angi securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Angi has violated federal… read more
May 29, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of enGene Therapeutics Inc. (“enGene” or “the Company”) (NASDAQ: ENGN). Investors who purchased enGene securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether enGene has violated… read more
May 28, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BP p.l.c. (“BP” or “the Company”) (NYSE: BP). Investors who purchased BP securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether BP has violated federal… read more
May 27, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zscaler, Inc. (“Zscaler” or “the Company”) (NASDAQ: ZS). Investors who purchased Zscaler securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Zscaler has violated federal… read more
May 27, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Grace Therapeutics, Inc. (“Grace” or “the Company”) (NASDAQ: GRCE). Investors who purchased Grace securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Grace has violated… read more